NUTX vs. LNSR, VYNE, MDAI, IPA, MODD, DRIO, FBIO, CYTH, POCI, and GSDI
Should you be buying Nutex Health stock or one of its competitors? The main competitors of Nutex Health include LENSAR (LNSR), VYNE Therapeutics (VYNE), Spectral AI (MDAI), ImmunoPrecise Antibodies (IPA), Modular Medical (MODD), DarioHealth (DRIO), Fortress Biotech (FBIO), Cyclo Therapeutics (CYTH), Precision Optics (POCI), and Global System Dynamics (GSDI). These companies are all part of the "medical" sector.
LENSAR (NASDAQ:LNSR) and Nutex Health (NASDAQ:NUTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
LENSAR has higher earnings, but lower revenue than Nutex Health. LENSAR is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Nutex Health has a net margin of -18.49% compared to Nutex Health's net margin of -34.11%. Nutex Health's return on equity of -40.53% beat LENSAR's return on equity.
LENSAR currently has a consensus price target of $8.00, suggesting a potential upside of 151.57%. Nutex Health has a consensus price target of $15.00, suggesting a potential upside of 2,149.89%. Given LENSAR's higher probable upside, analysts clearly believe Nutex Health is more favorable than LENSAR.
Nutex Health received 1 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 100.00% of users gave Nutex Health an outperform vote while only 38.46% of users gave LENSAR an outperform vote.
40.2% of LENSAR shares are owned by institutional investors. Comparatively, 5.3% of Nutex Health shares are owned by institutional investors. 66.0% of LENSAR shares are owned by insiders. Comparatively, 48.5% of Nutex Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, LENSAR and LENSAR both had 1 articles in the media. Nutex Health's average media sentiment score of 0.59 beat LENSAR's score of 0.00 indicating that LENSAR is being referred to more favorably in the media.
LENSAR has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Nutex Health has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Summary
Nutex Health beats LENSAR on 8 of the 15 factors compared between the two stocks.
Get Nutex Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nutex Health Competitors List
Related Companies and Tools
